1 Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Otolaryngol Head Neck Surg. 2018 Jan;158(1):43-53. doi: 10.1177/0194599817733735. Epub 2017 Sep 26.
Objectives Dexmedetomidine has sympatholytic, sedative, anesthetic, and analgesic effects, as well as vasoconstrictive effects, which may help prevent hypotension under general anesthesia. This meta-analysis aimed to perform a systematic review of the literature and investigate the effect of dexmedetomidine on perioperative morbidity following nasal surgery and its adverse effects. Data Sources MEDLINE, SCOPUS, and the Cochrane database. Review Methods Two authors independently searched the databases from their inception to March 2017. Studies were selected that compared perioperative dexmedetomidine administration (dexmedetomidine groups) with a placebo or remifentanil (control groups) with regard to intraoperative morbidity, including surgical time, bleeding amount, hypotension, and bradycardia during operation, and postoperative morbidity, such as emergence agitation, nausea and vomiting, and sedation after operation. Results Surgical time, intraoperative blood loss, dose of inhaled anesthetic gas, dose of fentanyl, postoperative pain, and incidence of emergence agitation were significantly lower in the dexmedetomidine group versus the placebo group. In contrast, there were no significant differences in intraoperative hemodynamic stability and postoperative residual sedation and nausea and vomiting between groups. Additionally, compared with remifentanil (a currently widely used agent), dexmedetomidine was superior in view of postoperative pain and intraoperative blood pressure control. Conclusion This meta-analysis shows that the systemic administration of dexmedetomidine can decrease surgical time, intraoperative blood loss, and doses of intraoperative inhaled anesthetic gas and fentanyl as compared with placebo. It can also decrease postoperative pain and incidence of the emergence agitation. Due to the small number of studies, further clinical trials are needed to confirm these results.
右美托咪定具有交感神经阻滞、镇静、麻醉和镇痛作用,以及血管收缩作用,这可能有助于预防全身麻醉下的低血压。本荟萃分析旨在对文献进行系统评价,并研究右美托咪定对鼻手术围手术期发病率的影响及其不良反应。
MEDLINE、SCOPUS 和 Cochrane 数据库。
两位作者独立检索了从数据库建立到 2017 年 3 月的数据。研究比较了围手术期给予右美托咪定(右美托咪定组)与安慰剂或瑞芬太尼(对照组)对术中发病率的影响,包括手术时间、术中出血量、术中吸入麻醉剂用量、芬太尼用量、术中低血压和心动过缓以及术后发病率,如苏醒期躁动、恶心呕吐和术后镇静。
与安慰剂组相比,右美托咪定组的手术时间、术中出血量、吸入麻醉剂用量、芬太尼用量、术后疼痛和苏醒期躁动发生率明显降低。而术中血流动力学稳定性和术后残留镇静、恶心呕吐发生率两组间无显著差异。此外,与瑞芬太尼(一种目前广泛使用的药物)相比,右美托咪定在术后疼痛和术中血压控制方面具有优势。
本荟萃分析表明,与安慰剂相比,全身给予右美托咪定可减少手术时间、术中出血量以及术中吸入麻醉剂和芬太尼的用量,还可减少术后疼痛和苏醒期躁动的发生率。由于研究数量较少,需要进一步的临床试验来证实这些结果。